No Domestic Approvals Yet for Dedicated Fetroja Testing Kits
Poor Market Potential Under Restricted-Use System...Companies Reluctant to Enter
"Diagnostic and Infection-Control Systems Must Be Established Alongside New Drug Introduction"

A new-concept antibiotic targeting what is considered the "most powerful antibiotic-resistant bacteria" has been introduced in Korea for the first time in nine years, but experts point out that there is a gap in the diagnostic system to support it. This is because no dedicated testing tool (kit) has been introduced in Korea to confirm in advance whether the new drug will actually be effective for patients.


According to the medical community on February 12, there are still no cases in which a kit that can confirm the drug response (susceptibility) of the cephalosporin antibiotic Fetroja, recently introduced to Korea by Jeil Pharmaceutical, has obtained domestic approval. Overseas, susceptibility testing kits specialized for this drug have already been commercialized, but foreign companies that developed them are reportedly reluctant to enter the Korean market.


Fetroja is the world's first antibiotic that combines a "siderophore" structure. It targets gram-negative bacteria, which have a double membrane and carry a high risk of developing resistance. By using the bacteria's iron uptake channels to penetrate inside, it adopts a "Trojan horse" strategy that bypasses the outer membrane barrier that has blocked existing antibiotics.

Product image of Thermo Fisher Scientific’s antibiotic susceptibility testing kit, the Sensititre Cefiderocol MIC Plate, which can measure the minimum inhibitory concentration (MIC) of Fetroja (generic name cefiderocol). Thermo Fisher Scientific

Product image of Thermo Fisher Scientific’s antibiotic susceptibility testing kit, the Sensititre Cefiderocol MIC Plate, which can measure the minimum inhibitory concentration (MIC) of Fetroja (generic name cefiderocol). Thermo Fisher Scientific

View original image

Although it is being evaluated as an alternative to fill the treatment gap for antibiotic-resistant bacteria, the introduction of a dedicated susceptibility testing kit is being delayed. Low market potential is cited as the main reason.


New antibiotics are strictly controlled in terms of target patients and indications to prevent the spread of resistance. Because the volume of use is low, the demand for testing is also limited. Most reimbursement fees for antibiotic susceptibility testing are fixed, so if the number of tests is not sufficient, it is difficult for companies to generate profit. The fact that the approval process typically takes 1 to 2 years is also cited as a factor that makes foreign companies hesitant to enter the Korean market.


The problem is that using antibiotics without confirming their effectiveness can significantly increase the risk of resistance spreading.


Antibiotic treatment generally proceeds in two stages. In the early phase of infection, before the causative pathogen has been identified, "empirical therapy" is administered first, in which antibiotics are chosen based on clinical judgment. After that, once culture and susceptibility testing results are available, treatment is switched to "definitive therapy" using an antibiotic that has been proven effective against the identified pathogen.


If susceptibility testing is not sufficiently performed, it becomes difficult to promptly transition to definitive therapy. The longer empirical therapy continues, the more unnecessary exposure to antibiotics increases, and this in turn raises the risk of resistance spreading.


Experts stress that for newer antibiotics, susceptibility testing should be conducted in parallel from the early stages of introduction. This is because even for a new drug, bacteria may already possess genes that can neutralize it. They explain that antibiotics should be used only when their effectiveness has been confirmed through susceptibility testing, in order to reduce unnecessary antibiotic exposure and slow the spread of resistance.


Lee Hyukmin, a professor in the Department of Laboratory Medicine at Severance Hospital, said, "It takes several years for a new drug to be introduced into Korea after it is launched overseas, but resistance spreads rapidly during that time," adding, "If the diagnostic system and infection control system are not established together with the introduction of a new drug, it will be difficult to prevent another wave of resistance from spreading."


The establishment of a system that comprehensively manages antibiotic treatment, diagnostics, and infection control is expected to become even more important. The World Health Organization (WHO) has called the problem of antibiotic resistance a "silent pandemic" and, in 2019, designated it as one of the "top 10 global public health threats facing humanity."



In clinical practice, infections caused by resistant bacteria are one of the leading causes of death among patients. Kim Taehyung, a professor in the Division of Infectious Diseases at Soonchunhyang University Seoul Hospital, emphasized, "Antibiotic-resistant bacteria are not just a problem for certain patient groups, but are linked to the 'final cause of death' in nearly all severe diseases."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing